UB Paderborn / Katalog / Suche / in CDI

Richter transformation driven by Epstein–Barr virus reactivation during therapy‐related immunosuppression in chronic lymphocytic leukaemia

The Journal of pathology, 2018-05, Vol.245 (1), p.61-73

2018

Link zum Volltext

Verfügbarkeit prüfen

Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)

Bone marrow transplantation (Basingstoke), 2020-03, Vol.55 (3), p.562-569

2020

Link zum Volltext

Verfügbarkeit prüfen

Serology-based therapeutic strategy in SARS-CoV-2-infected patients

International immunopharmacology, 2021-12, Vol.101 (Pt B), p.108214-108214, Article 108214

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study

British journal of haematology, 2020-03, Vol.188 (5), p.661-673

2020

Link zum Volltext

Verfügbarkeit prüfen

Peripheral blood natural killer cell depletion is associated with severe pneumonia in coronavirus disease-2019 (COVID-19)

Irish journal of medical science, 2022-06, Vol.191 (3), p.1453-1455

2022

Link zum Volltext

Verfügbarkeit prüfen

Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Immunology, 2014-08, Vol.142 (4), p.536-550

2014

Link zum Volltext

Verfügbarkeit prüfen

Maintenance therapy with ex vivo expanded lymphokine‐activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

British journal of haematology, 2020-06, Vol.189 (6), p.1064-1073

2020

Link zum Volltext

Verfügbarkeit prüfen

First‐line use of rituximab correlates with increased overall survival in late post‐transplant lymphoproliferative disorders: retrospective, single‐centre study

European journal of haematology, 2017-01, Vol.98 (1), p.38-43

2017

Link zum Volltext

Verfügbarkeit prüfen

Follicular lymphoma (FL): immunological tolerance theory in FL

Human immunology, 2017-02, Vol.78 (2), p.138-145

2017

Link zum Volltext

Verfügbarkeit prüfen

Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab

Annals of hematology, 2014-11, Vol.93 (11), p.1879-1887

2014

Link zum Volltext

Verfügbarkeit prüfen

A new case of Bicêtre hemoglobin in an adult male: clinical observations over a period of four years

Annals of hematology, 2022-03, Vol.101 (3), p.701-702

2022

Link zum Volltext

Verfügbarkeit prüfen

Left ventricular septal lipoma

Journal of cardiac surgery, 2018-12, Vol.33 (12), p.791-792

2018

Link zum Volltext

Verfügbarkeit prüfen

Immunological aspects in chronic lymphocytic leukemia (CLL) development

Annals of hematology, 2012-07, Vol.91 (7), p.981-996

2012

Link zum Volltext

Verfügbarkeit prüfen

IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis

European journal of immunology, 2008-02, Vol.38 (2), p.576-586

2008

Link zum Volltext

Verfügbarkeit prüfen

The top ten clues to understand the origin of chronic lymphocytic leukemia (CLL)

Journal of autoimmunity, 2015-01, Vol.56, p.81-86

2015

Link zum Volltext

Verfügbarkeit prüfen

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Clinical lymphoma, myeloma and leukemia, 2021-12, Vol.21 (12), p.e985-e999

2021

Link zum Volltext

Verfügbarkeit prüfen

Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity

Immunologic research, 2016-04, Vol.64 (2), p.548-557

2016

Link zum Volltext

Verfügbarkeit prüfen

Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma

Leukemia & lymphoma, 2013-12, Vol.54 (12), p.2753-2755

2013

Link zum Volltext

Verfügbarkeit prüfen

Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia

Immunotherapy, 2018-05, Vol.10 (6), p.491-499

2018

Link zum Volltext

Verfügbarkeit prüfen

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race

Future science OA, 2019-03, Vol.5 (3), p.FSO375

2019

Link zum Volltext

Verfügbarkeit prüfen

Common variable immunodeficiency and Evans syndrome complicated by autoimmune hemolysis due to anti-Jka auto-antibodies

Leukemia & lymphoma, 2008-01, Vol.49 (6), p.1220-1222

2008

Link zum Volltext

Verfügbarkeit prüfen

Autoimmunity and lymphoma: Is mantle cell lymphoma a mistake of the receptor editing mechanism?

Leukemia research, 2009-11, Vol.33 (11), p.1437-1439

2009

Link zum Volltext

Verfügbarkeit prüfen

Overall reduction in antibody production could contribute to generate pathogenic autoantibodies and autoimmune manifestations

Clinical rheumatology, 2009-03, Vol.28 (3), p.361-363

García-Muñoz, Ricardo

2009

Link zum Volltext

Verfügbarkeit prüfen

Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab–bendamustine

Annals of hematology, 2014-04, Vol.93 (4), p.699-702

2014

Link zum Volltext

Verfügbarkeit prüfen

Modern times: back to past, back to future

Medicina clinica, 2012-07, Vol.139 (4), p.180

2012

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Richter transformation driven by Epstein–Barr virus reactivation during therapy‐related immunosuppression in chronic lymphocytic leukaemia

Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)

Serology-based therapeutic strategy in SARS-CoV-2-infected patients

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study

Peripheral blood natural killer cell depletion is associated with severe pneumonia in coronavirus disease-2019 (COVID-19)

Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Maintenance therapy with ex vivo expanded lymphokine‐activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

First‐line use of rituximab correlates with increased overall survival in late post‐transplant lymphoproliferative disorders: retrospective, single‐centre study

Follicular lymphoma (FL): immunological tolerance theory in FL

Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab

A new case of Bicêtre hemoglobin in an adult male: clinical observations over a period of four years

Left ventricular septal lipoma

Immunological aspects in chronic lymphocytic leukemia (CLL) development

IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis

The top ten clues to understand the origin of chronic lymphocytic leukemia (CLL)

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity

Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma

Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race

Common variable immunodeficiency and Evans syndrome complicated by autoimmune hemolysis due to anti-Jka auto-antibodies

Autoimmunity and lymphoma: Is mantle cell lymphoma a mistake of the receptor editing mechanism?

Overall reduction in antibody production could contribute to generate pathogenic autoantibodies and autoimmune manifestations

Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab–bendamustine

Modern times: back to past, back to future

Suchergebnisse filtern